Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenue
31
28
33
43
30
15
Revenue Growth (YoY)
35%
-15%
-23%
43%
100%
275%
Cost of Revenue
13
12
13
15
12
9
Gross Profit
17
15
20
27
17
5
Selling, General & Admin
45
41
41
37
38
27
Research & Development
--
8
9
15
14
11
Operating Expenses
60
50
45
53
52
38
Other Non Operating Income (Expenses)
0
0
0
0
0
0
Pretax Income
-43
-38
-26
-37
-35
-47
Income Tax Expense
--
0
0
1
0
--
Net Income
-46
-39
-26
-41
-36
-48
Net Income Growth
70%
50%
-37%
14%
-25%
4%
Shares Outstanding (Diluted)
16
15.34
13.36
13.64
13.61
11.04
Shares Change (YoY)
18%
15%
-2%
0%
23%
15%
EPS (Diluted)
-2.9
-2.56
-2.02
-3.01
-2.69
-4.37
EPS Growth
43%
27%
-33%
12%
-38%
-9%
Free Cash Flow
--
-29
-22
-26
-42
-45
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
54.83%
53.57%
60.6%
62.79%
56.66%
33.33%
Operating Margin
-135.48%
-121.42%
-75.75%
-60.46%
-116.66%
-220%
Profit Margin
-148.38%
-139.28%
-78.78%
-95.34%
-120%
-320%
Free Cash Flow Margin
--
-103.57%
-66.66%
-60.46%
-140%
-300%
EBITDA
--
-32
-22
-24
-34
-32
EBITDA Margin
--
-114.28%
-66.66%
-55.81%
-113.33%
-213.33%
D&A For EBITDA
--
2
3
2
1
1
EBIT
-42
-34
-25
-26
-35
-33
EBIT Margin
-135.48%
-121.42%
-75.75%
-60.46%
-116.66%
-220%
Effective Tax Rate
--
0%
0%
-2.7%
0%
--
Follow-Up Questions
What are James Monroe Capital Corp's key financial statements?
According to the latest financial statement (Form-10K), CASI Pharmaceuticals Inc has a total asset of $53, Net loss of $-39
What are the key financial ratios for JMON?
CASI Pharmaceuticals Inc's Current ratio is 1.03, has a Net margin is -139.28, sales per share of $1.82.
How is James Monroe Capital Corp's revenue broken down by segment or geography?
CASI Pharmaceuticals Inc largest revenue segment is Pharmaceutical Products, at a revenue of 28,537,000 in the most earnings release.For geography, China is the primary market for CASI Pharmaceuticals Inc, at a revenue of 28,537,000.
Is James Monroe Capital Corp profitable?
no, according to the latest financial statements, CASI Pharmaceuticals Inc has a net loss of $-39
Does James Monroe Capital Corp have any liabilities?
yes, CASI Pharmaceuticals Inc has liability of 51
How many outstanding shares for James Monroe Capital Corp?
CASI Pharmaceuticals Inc has a total outstanding shares of 15.49